Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Experimentation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Experimentation. Displaying page 1 of 1.
    EudraCT Number: 2004-004825-87 Sponsor Protocol Number: R00002 VE 201 Start Date*: 2005-04-22
    Sponsor Name:Pierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre
    Full Title: Efficacy and safety of 0,1%, 0,5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups.
    Medical condition: Psoriasis of the skin is frequently accompanied by nail changes: between 10 and 78% of psoriatic patients suffer from changes of the nails. More than 50% of patients with nail psoriasis have pain b...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10028703 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-019086-28 Sponsor Protocol Number: AQUARIUS Start Date*: 2011-02-21
    Sponsor Name:UO Divisione Nefrologia, Dialisi e Trapianto renale
    Full Title: Multicenter, no-profit, open, single sequence cross-over study on effectiveness and safety of anti-rejection therapy based on modified release Tacrolimus(Advagraf)and on patients quality of life an...
    Medical condition: Kidney transplant patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023439 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002742-11 Sponsor Protocol Number: ML20005 Start Date*: 2007-04-18
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: MULTICENTER PHASE II TRIAL OF TARCEVA COMBINED WITH FIXED DOSE-RATE GEMCITABINE INFUSION AS FIRST LINE TREATMENT OF ADVANCED, UNRESECTABLE PANCREATIC CANCER
    Medical condition: Advanced pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033633 Pancreatic neoplasms malignant (excl islet cell and carcinoid) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003774-32 Sponsor Protocol Number: N/A Start Date*: 2022-01-26
    Sponsor Name:DIPARTIMENTO BIOMEDICINA E PREVENZIONE UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA
    Full Title: Enhancing Treatment in Persistent Glioblastoma through AGuIX Nanoparticles for Precision Radiotherapy (NanoGBM-Precision): A Phase II, monocenter, open-label, single-arm, no-profit clinical trial.
    Medical condition: Persistent Glioblastoma Multiforme, grade IV
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001036-21 Sponsor Protocol Number: PCaRestaging-PET/MR Start Date*: 2020-03-04
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Phase II monocentric study on prostate cancer restaging using PET/MR with innovative radiotracers
    Medical condition: Radically treated patient for prostate cancer presenting a biochemical recurrence of disease (PSA: > o = 0.2 ng/mL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001034-18 Sponsor Protocol Number: PETMR-Staging-PCa1 Start Date*: 2020-03-04
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Phase II monocentric study to evaluate a novel approach for staging prostate cancer patients by using a fully integrated hybrid PET/MRI
    Medical condition: Patient diagnosed with prostatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001949-26 Sponsor Protocol Number: 26062-22061 Start Date*: 2009-05-05
    Sponsor Name:EORTC European Organisation for Research and Treatment of Cancer
    Full Title: A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTS
    Medical condition: Elderly (>65 years of age) patients with newly diagnosed, and histopathologically confirmed, glioblastoma multiforme (GBM, WHO grade IV) , who have had prior surgery/biopsy at diagnosis and who are...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FR (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020348-36 Sponsor Protocol Number: ACO-002 Start Date*: 2011-01-31
    Sponsor Name:Alchemia Oncology Pty Ltd
    Full Title: Randomized double-blind Phase III trial of FOLF(HA)iri vs FOLFIRI for second or third line therapy in irinotecan-naïve patients with metastatic colorectal cancer
    Medical condition: Metastatic colorectal cancer (mCRC)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001893-28 Sponsor Protocol Number: 30-04 Start Date*: 2005-11-18
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer
    Medical condition: Post-menopausal women, histologically or cytologically confirmed, receptor-positive, adequately excised, primary breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004568-27 Sponsor Protocol Number: CLAP016A2303/EGF108919 Start Date*: 2008-10-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer
    Medical condition: HER2/ErbB2 positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) NL (Completed) ES (Prematurely Ended) IT (Completed) BE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 21:06:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA